Keywords: biogen/elan, tysabri, yields, strong, ph, iii, data

Biogen/Elan's Tysabri yields strong Ph III data

Article | 09 October 2006

Print This

US drugmaker Biogen Idec and Ireland's Elan Corp say that data from the Phase III AFFIRM monotherapy study demonstrated that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in